Neuro-Bio
Neuro-Bio is a privately owned biotech company focused on neurodegenerative diseases, particularly Alzheimer’s disease. They have discovered a novel molecule, T14, which is toxic in the adult brain and a key driver of neurodegeneration. The company is developing a pre-symptomatic biomarker and drug based on this mechanism, aiming to treat Alzheimer’s disease with a first-in-class approach based on a novel biological mechanism.
Industries
Nr. of Employees
small (1-50)
Neuro-Bio
Abingdon-On-Thames, England, United Kingdom
Patents
Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
US-11033609-B2
View Details
Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis
US-11033609-B2
View DetailsProducts
Prototype therapeutic peptide blocker (cyclized peptide)
Preclinical peptide candidate designed to block the activity of the neurotoxic peptide; demonstrated prevention of memory dysfunction in AD model mice and target engagement in human tissue studies.
Pre-symptomatic biomarker assay for a neurodegeneration-associated peptide
Analytical assay concept for early detection of a peptide marker of neurodegeneration, applied to brain tissue and skin, intended for pre-symptomatic identification of disease processes.
T14
A novel 14 amino acid bioactive peptide derived from the C terminus of AChE that is neurotoxic in the adult brain and acts as a key driver of neurodegeneration.
T14 Saliva and Nasal Secretions Biomarker
A biomarker with diagnostic and prognostic potential for pre-symptomatic Alzheimer's disease using detection of T14 via nasal secretions using a lateral flow test with aptamer technology and saliva using mass spectrometry.
T14 Nasal LFT Diagnostic
A diagnostic test utilizing aptamer technology for the detection of T14 in nasal secretions with diagnostic and prognostic potential.
T14 Saliva Diagnostic Test
A clinical diagnostic test utilizing immunodetection technology for the detection of T14 in saliva.
Prototype therapeutic peptide blocker (cyclized peptide)
Preclinical peptide candidate designed to block the activity of the neurotoxic peptide; demonstrated prevention of memory dysfunction in AD model mice and target engagement in human tissue studies.
Pre-symptomatic biomarker assay for a neurodegeneration-associated peptide
Analytical assay concept for early detection of a peptide marker of neurodegeneration, applied to brain tissue and skin, intended for pre-symptomatic identification of disease processes.
T14
A novel 14 amino acid bioactive peptide derived from the C terminus of AChE that is neurotoxic in the adult brain and acts as a key driver of neurodegeneration.
T14 Saliva and Nasal Secretions Biomarker
A biomarker with diagnostic and prognostic potential for pre-symptomatic Alzheimer's disease using detection of T14 via nasal secretions using a lateral flow test with aptamer technology and saliva using mass spectrometry.
T14 Nasal LFT Diagnostic
A diagnostic test utilizing aptamer technology for the detection of T14 in nasal secretions with diagnostic and prognostic potential.
T14 Saliva Diagnostic Test
A clinical diagnostic test utilizing immunodetection technology for the detection of T14 in saliva.
Services
Joint research programs with academic and industry partners to investigate mechanisms, develop biomarkers and evaluate therapeutic candidates.
Joint research programs with academic and industry partners to investigate mechanisms, develop biomarkers and evaluate therapeutic candidates.
Expertise Areas
- Neurodegeneration mechanism research
- Biomarker discovery and validation
- Preclinical drug development
- Molecular and cellular neuroscience
Key Technologies
- Peptide biology
- Ligand-binding assays
- In vitro dose–response assays
- Cell culture and molecular biology (PCR)
News & Updates
Neuro-Bio would like to take this time to wish you all a very Merry Christmas and a Happy New Year. Please note, we will be closed from 16:00 Friday 18 December 2020 and will reopen on Monday 4 January 2021 with our normal business hours.
Neuro-Bio attended the London Biotechnology Show, bringing together global thought leaders and innovators in biotech.
A farewell message from Catalina Vigil Cardenal reflecting on her time at Neuro-Bio.
Baroness Susan Greenfield, CEO & Founder of Neuro-Bio, participated as keynote speaker and panelist at the summit.
Michelle Vandekleut joins Neuro-Bio as Executive Assistant to the CEO & Founder.
Neuro-Bio hosted a joint lunchtime innovation session with UKAEA at Culham Campus.
Neuro-Bio would like to take this time to wish you all a very Merry Christmas and a Happy New Year. Please note, we will be closed from 16:00 Friday 18 December 2020 and will reopen on Monday 4 January 2021 with our normal business hours.
Neuro-Bio attended the London Biotechnology Show, bringing together global thought leaders and innovators in biotech.
A farewell message from Catalina Vigil Cardenal reflecting on her time at Neuro-Bio.
Baroness Susan Greenfield, CEO & Founder of Neuro-Bio, participated as keynote speaker and panelist at the summit.
Michelle Vandekleut joins Neuro-Bio as Executive Assistant to the CEO & Founder.
Neuro-Bio hosted a joint lunchtime innovation session with UKAEA at Culham Campus.